J. Bogdanos

发表

Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free s

M. Koutsilieris, P. Msaouel, T. Dimopoulos, 2007, Clinical chemistry and laboratory medicine.

Combination of somatostatin analogues and dexamethasone (antisurvival‐factor concept) with luteinizing hormone‐releasing hormone in androgen ablation‐refractory prostate cancer with bone metastasis

M. Koutsilieris, A. Sourla, A. Halapas, 2007, BJU international.

Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2006, Anticancer research.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach

M. Koutsilieris, R. Tenta, T. Dimopoulos, 2006, Expert opinion on investigational drugs.

Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.

C. Mitsiades, M. Koutsilieris, R. Tenta, 2003, Endocrine-related cancer.

Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement

M. Koutsilieris, D. Tiblalexi, R. Tenta, 2002, Molecular medicine.

Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).

E. Petridou, M. Koutsilieris, N. Dessypris, 2006, Anticancer research.

Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2002, Expert opinion on investigational drugs.

Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2004, Clinical Cancer Research.

Bone Metastasis Microenvironment Participates in the Development of Androgen Ablation Refractoriness and Chemotherapy Resistance of Prostate Cancer Cells Residing in the Skeleton: Clinical Implications

M. Koutsilieris, D. Tiblalexi, R. Tenta, 2005 .

The large bladder diverticulum in children.

P. Androulakakis, J. Bogdanos, A. Stephanidis, 2005, Journal of pediatric urology.

Morbidity of prophylactic inguinal lymphadenectomy with saphenous vein preservation for squamous cell penile carcinoma

C. Milathianakis, J. Bogdanos, D. Karamanolakis, 2005, International journal of urology : official journal of the Japanese Urological Association.

Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.

M. Koutsilieris, J. Bogdanos, D. Karamanolakis, 2004, Anticancer research.

RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2006 .

Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.

M. Koutsilieris, C. Milathianakis, J. Bogdanos, 2003, Anticancer research.

International Congress on Hormonal Steroids and Hormones and Cancer Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton

C. Mitsiades, M. Koutsilieris, R. Tenta, 2003 .